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RET gene rearrangements (RET/PTCs) represent together with BRAF point mutations the
two major groups of mutations involved in papillary thyroid carcinoma (PTC) initiation and
progression. In this review, we will examine the mechanisms involved in RET/PTC -induced
thyroid cell transformation. In detail, we will summarize the data on the molecular mech-
anisms involved in RET/PTC formation and in its function as a dominant oncogene, on
the activated signal transduction pathways and on the induced gene expression modiﬁ-
cations. Moreover, we will report on the effects of RET/PTCs on the tumor microenviron-
ment. Finally, a short review of the literature on RET/PTC prognostic signiﬁcance will be
presented.
Keywords: thyroid carcinoma, papillary thyroid carcinoma, RET/PTC
INTRODUCTION
Thyroid cancer is the most common malignant tumor of the
endocrine system and accounts for approximately 3% of all newly
diagnosed cancer cases in the United States1. The most frequent
type of thyroid cancer is papillary thyroid carcinoma (PTC),which
constitutes ∼80% of all cases. PTC frequently has genetic alter-
ations leading to the activation of the mitogen-activated protein
kinase (MAPK) signaling pathway. Those include RET/PTC and
NTRK1 rearrangements and BRAF and RAS point mutations
(Figure 1). Mutations involving one of these genes are found in
about 70% of papillary carcinomas and they rarely overlap in the
same tumor (Kimura et al., 2003; Puxeddu et al., 2004; Carta et al.,
2006; Kondo et al., 2006).
In this review,we will focus on RET/PTC rearrangements sum-
marizing the available data on themolecularmechanisms involved
in their formation and in their function as dominant oncogenes,
on the activated signal transduction pathways, and on induced
gene expression modiﬁcations. Moreover, we will report on their
effects on tumor microenvironment.
GENERAL FEATURES OF RET/PTCs
The RET (REarranged during Transfection) proto-oncogene is
located in the pericentromeric region of chromosome 10q11.2
and spans 21 exons (Takahashi et al., 1985). RET encodes for a
cell membrane receptor tyrosine kinase (TK), which is expressed
in neuroendocrine cells (including thyroid C cells and adrenal
1http://seer.cancer.gov/csr/1975_2008/
medullary cells), neural cells, urogenital tract cells, and testis
germ cells (Wells and Santoro, 2009). RET protein displays an
extracellular portion which contains four cadherin-like repeats,
a calcium-binding site and a cysteine-rich region (Anders et al.,
2001), a transmembrane portion and an intracellular portion,
which contains the juxtamembrane domain, the TK domain,
split in two subdomains by an insert of 14 amino acids, and
a C-terminal tail (Knowles et al., 2006). Glial cell line-derived
neurotrophic factor, neurturin, artemin, and persephin have been
shown to be RET ligands (Durbec et al., 1996; Sariola and Saarma,
2003). They bind RET in conjunction with one of four glycosyl-
phosphatidylinositol-anchored co-receptors, designated GDNF-
family α receptors (GFRα) 1, 2, 3, and 4 (Puxeddu and Fagin,
2001).
Structurally, RET-TK adopts the typical protein kinase bi-
lobate structure consisting of a small N-lobe and a large C-lobe
connectedby a short linker (Knowles et al., 2006).However, at vari-
ance with most kinases which are monomeric and auto-inhibited
in cis by the C-lobe activation loop (A-loop) that maintains
the kinase pocket closed in unstimulated conditions, RET-TK is
already a dimer in the resting state. It adopts a trans-inhibited
head-to-tail inactive dimer conformation in which the substrate-
binding site of each monomer is occluded by the controlateral
one (Knowles et al., 2006). While in other kinases ligand bind-
ing causes dimerization, rearrangement of the A-loop, and kinase
activation, interaction of RET with the GDNF/GFRα complex
probably causes a conformational change that relieves the trans-
inhibition and favors the formation of active dimers (Knowles
et al., 2006).
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FIGURE 1 | Gene mutations involved in PTC carcinogenesis. PTC is driven
by genetic alterations leading to the activation of the mitogen-activated
protein kinase (MAPK) signaling pathway. Those include RET/PTC and NTRK1
rearrangements and RAS and BRAF point mutations.
FIGURE 2 | Formation of RET/PTC. (A) RET codes a membrane protein of
the tyrosine kinase receptor family which is not expressed or expressed at
very low levels in thyroid follicular cells. (B) RET activation can occur through
chromosomal rearrangements that involve the gene. (C)These
rearrangements result in the in-frame fusion of RET intracellular domain
coding region with the 5′ end of heterologous genes. The resulting chimeric
sequence codes an oncoprotein, called RET/PTC, that drives the development
of PTC.
In thyroid follicular cells, RET is not expressed or expressed
at very low levels, but RET activation can occur through chro-
mosomal rearrangements that involve the gene. They result in
the in-frame fusion of part of RET intracellular domain cod-
ing region (including that coding for the TK from residue E713
and the carboxy-terminal tail) with the 5′ end of heterologous
genes (Figure 2). The resulting chimeric sequences are called
RET/PTC and at least 13 variants have been reported to date, that
differ according to the 5′ partner gene involved in the rearrange-
ment (Castellone and Santoro, 2008) (Figure 3). The two most
common rearrangement types are RET/PTC1 and RET/PTC3
which account alone for more than 90% of all rearrangements
found in PTCs. RET/PTC1 is formed by fusion with the coiled-coil
domain containing gene 6 (CCDC6, formely called H4/D10S170),
and RET/PTC3 by fusion with the nuclear receptor coactivator
gene-4 (NCOA4, formely called RFG/ELE1/ARA70; Grieco et al.,
1990; Santoro et al., 1994). RET/PTC1 and RET/PTC3 are intra-
chromosomal paracentric inversions because both genes partici-
pating in the fusion are located on chromosome 10q (Pierotti et al.,
1992; Minoletti et al., 1994). At variance RET/PTC2 and the other
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rare types of RET/PTC are inter-chromosomal translocations
(Castellone and Santoro, 2008).
Several mechanisms sustain the conversion of RET in a dom-
inant oncogene for thyroid follicular cells after formation of
RET/PTCs (Figure 4). In ﬁrst instance, the ubiquitously expressed
promoter of the fusion partner warrants ectopic RET expression
in the cells harboring the rearrangement. Moreover, the partner
genes are predicted to provide one or more coiled-coil domains
that are essential for dimerization and ligand-independent activa-
tion of the truncated RET protein (Bongarzone et al., 1993; Tong
et al., 1997; Monaco et al., 2001). Furthermore, RET/PTCs lack
FIGURE 3 | Schematic drawing of RET/PTC variants. At least 13
RET/PTC variants have been reported to date, that differ according to the 5′
partner gene involved in the rearrangement.
the intracellular juxtamembrane domain which forms an integral
part of the autoinhibited RET dimer interface (Knowles et al.,
2006). As a consequence the TK domain is favored to adopt the
active conformation. Finally, the delocalization of the rearranged
protein to the cytosol is also expected to contribute to activa-
tion of the oncogene (Castellone and Santoro, 2008). In ﬁrst
instance, the altered subcellular localization uncouples RET/PTCs
from receptor-mediated endocytosis and lysosomal degradation,
leading to increased protein stability (Richardson et al., 2009).
Moreover, it could prevent RET/PTC from interacting with nega-
tive regulators located at plasma membrane level, i.e., the tyrosine
phosphatase ProteinTyrosine Phosphates Receptor type-J (PTPRJ;
Iervolino et al., 2006).
The possible functional interactions between RET/PTC and
EGFR in PCCL3 cells was examined after the observation that the
epidermal growth factor receptor (EGFR) kinase inhibitor PKI166
decreased RET/PTC kinase auto-phosphorylation and activation
of downstream effectors in thyroid cells (Croyle et al., 2008). This
study showed that RET/PTC induces EGFR gene expression and
kinase activation in part through MAPK signaling and forms a
complex with EGFR in a kinase-independent manner. In turn
EGFR stimulates RET phosphorylation (Croyle et al., 2008).
It is well known that PTC in general, but those harboring
RET/PTC rearrangements in particular, present relatively indo-
lent phenotypes compared with RET -related medullary thyroid
carcinomas (MTC; Elisei et al., 2008). Considering that RET/PTCs
possess similar if not greater oncogenic potential than membrane-
bound RET when expressed at similar levels (Richardson et al.,
2009), the explanation of this phenotype difference has to be
searched in divergences of the oncogene expression levels or of the
FIGURE 4 | Mechanism of RET/PTC activation. (1) The ubiquitously
expressed promoter of the fusion partner warrants ectopic RET expression in
the cells harboring the rearrangement. (2) The partner genes provide one or
more coiled-coil domains that are essential for dimerization and
ligand-independent activation of the truncated RET protein. (3) The lack of the
inhibitory intracellular juxtamembrane domain favors RET/PTC to adopt the
active conformation. (4) The delocalization of the rearranged protein to the
cytosol abolishes receptor-mediated endocytosis and lysosomal degradation,
leading to increased protein stability, and interaction with negative regulators
located at plasma membrane level. (5) RET fusion genes appear to code
negative modulators of transformation. Thus, their structural alteration might
contribute to the oncogenic potential of the RET/PTC rearrangements.
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cellular responsiveness to them in follicular and the C-cells in vivo.
Very recently,Richardson andothers demonstrated that expression
of RET/PTCs via the 5′ promoter region of CCDC6 and NCOA4
could result in lower expression of these oncoproteins, relative to
full-lengthRET,expressedoff its endogenouspromoter. These data
indicate that also transcript level modulates the inherent onco-
genicity of RET/PTC oncoproteins and that in vivo it is trumped
by the substitution of relatively weak promoters upstream of the
chimeric oncogene (Richardson et al., 2009).
It is plausible that also the structural alteration of the RET
fusion partners might contribute to the oncogenic potential of
the RET/PTC rearrangements. This is easily understandable for
the RET/PTC2 fusion partner PRKAR1A which encodes a cyclic
AMP-dependent protein kinase type I-regulatory subunit (Bon-
garzone et al., 1993). Indeed, it is known to be a bona ﬁde tumor
suppressor gene mutated in about half of Carney complex kin-
dreds (Kirschner et al., 2000). Moreover, its ablation in the mouse
induces the formation of thyroid tumors (Grifﬁn et al., 2004).
However, also CCDC6 (RET/PTC1) has been shown to possess
proapoptotic activity (Celetti et al., 2004) and to repress CREB1
transcriptional activity by recruiting histone deacetylase 1 and
protein phosphatase 1 proteins at the CRE site of the CREB1
target genes (Leone et al., 2010). Moreover, ERC1 (ELKS-RET )
has appeared to be a NF-kB regulator (Ducut Sigala et al., 2004;
Wu et al., 2006), TRIM33 (RET/PTC7 ) to interact with TGFβ sig-
naling intermediates Smad (Dupont et al., 2005; He et al., 2006),
and RFP (RFP-RET ) to act as a transcriptional repressor disabling
pRb-mediated differentiation (Shimono et al., 2000; Krützfeldt
et al., 2005).
Intriguingly, some of the RET fusion partners are found
rearranged in tumors other than PTC: TRIM24 (participating in
RET/PTC6) rearranges with BRAF in mouse hepatocellular carci-
nomas (Zhong et al., 1999); PMC1 (participating in PMC1-RET )
with JAK2 in chronic myeloid leukemia (Bousquet et al., 2005);
CCDC6 (participating in RET/PTC1) with the kinase domain of
the platelet-derived growth factor receptor-β in myeloproliferative
disorders (Kulkarni et al., 2000). Moreover, in thyroid carcinoma
cell lines and PTC samples CCDC6/H4 was shown to rearrange
with PTEN through an intra-chromosomal inversion forming
non-clonal H4/PTEN chimeric genes of unknown pathogenetic
signiﬁcance (Puxeddu et al., 2005b).
There are several lines of evidence pointing to RET/PTC
as a key ﬁrst step in thyroid cancer pathogenesis (Figure 5).
In ﬁrst instance, RET/PTC expression causes TSH-independent
FIGURE 5 | Lines of evidence pointing to RET/PTC as a key first step
in thyroid cancer pathogenesis. (A) RET/PTC expression causes
TSH-independent proliferation in thyroid follicular cells. PCCL3: Parental
well differentiated rat thyroid cell line. PC-PTC: PCCL3 cells stably
expressing RET/PTC1. +6H: Grown in the presence ofTSH. −6H: Grown in
the absence of TSH (Modiﬁed from Santoro et al. (1993) with permission
of the American Association for Cancer Research). (B) RET/PTC
expression causes downregulation of differentiation markers in thyroid
follicular cells. PC: Control parental PCCL3 cells. 1–4: Clones of PCCL3
cells stably expressing RET/PTC1. TG: Thyroglobulin. TSH-R: TSH receptor.
TPO: Thyroperoxidase. (From Santoro et al. (1993) with permission of the
American Association for Cancer Research). (C)Thyroid-speciﬁc
overexpression of either RET/PTC1 or RET/PTC3 in transgenic mice leads
to development of tumors with histological features consistent with PTC
(Jhiang et al., 1996; Santoro et al., 1996; Powell et al., 1998). (D) Occult
microscopic PTCs show high prevalence of RET/PTC expression (Viglietto
et al., 1995; Sugg et al., 1998). (E) Exposure of cell lines and fetal thyroid
explants to ionizing radiation, the major known risk factor for PTC, results
in induction of RET/PTC expression within hours (Ito et al., 1993; Mizuno
et al., 1997).
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proliferation and downregulation of differentiation markers in
thyroid follicular cells (Santoro et al., 1993). Moreover, thyroid-
speciﬁc overexpression of either RET/PTC1 (Jhiang et al., 1996;
Santoro et al., 1996) or RET/PTC3 (Powell et al., 1998) in trans-
genic mice leads to development of tumors with histological fea-
tures consistent with PTC. Furthermore, there is a high prevalence
of RET/PTC expression in occult microscopic PTC, believed to
represent an early step in the development of clinically signiﬁcant
cancers (Viglietto et al., 1995; Sugg et al., 1998). Finally, exposure
of cell lines (Ito et al., 1993) and fetal thyroid explants (Mizuno
et al., 1997) to ionizing radiation results in induction of expression
of RET/PTC within hours, supporting a direct role for radiation,
the major known risk factor for thyroid cancer, in the illegitimate
recombination of RET.
RET rearrangements have been considered exclusive of PTC.
Unexpectedly, this dogma was broken very recently by three inde-
pendent studies which simultaneously demonstrated the existence
of a novel RET rearrangement in 1–2% of lung carcinomas. In
this rearrangement, RET engages with KIF5B (the kinesin family
5B gene), located on chromosome 10p11.2, through a pericentric
inversion of chromosome 10 (Kohno et al., 2011; Lipson et al.,
2011; Takeuchi et al., 2011). Furthermore, one of these studies also
reported the occurrence of RET/PTC1 rearrangements in two lung
adenocarcinomas (Takeuchi et al., 2011).
Four variants of KIF5B-RET fusion have been described and
named on the basis of the last KIF5B and ﬁrst RET exon involved
in the fusion: K15;R12 (variant 1), K16;R12 (variant 2), K22;R12
(variant 3), K15;R11 (variant 4). All proteins encoded by the four
KIF5B-RET rearrangements appeared to retain the KIF5B coiled-
coil domain necessary for homodimerization and to hold the full
RET kinase domain, as other types of oncogenic RET fusion pro-
teins observed in PTC (Kohno et al., 2011; Lipson et al., 2011;
Takeuchi et al., 2011).
The mutually exclusive nature of the RET rearrangements and
other oncogenic alterations suggests that the KIF5B-RET fusion is
a driver mutation in lung carcinoma (Kohno et al., 2011; Lipson
et al., 2011).
KIF5B-RET expression in Ba/F3 cells led to oncogenic trans-
formation, as demonstrated by the occurrence of interleukin-3
(IL-3)-independent growth. These transformed cells resulted sen-
sitive to sunitinib, sorafenib, and vandetanib, which are all mul-
titarget kinase inhibitors of RET (Lipson et al., 2011), suggesting
that RET kinase inhibitors should be tested in prospective clinical
trials in individuals with lung carcinomas that harbor KIF5B-RET
rearrangements.
RET AND MEDULLARY THYROID CARCINOMA
Medullary thyroid carcinoma (MTC) is a malignant tumor arising
from thyroid C cells. It represents about 5% of all thyroid cancers
and can be hereditary (about 25%of cases) or sporadic (remaining
cases; Stratakis and Ball, 2000). Familial forms develop in the con-
test of Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome
in which MTC can be the sole manifestation of the disease (Famil-
ial Medullary Thyroid Carcinoma – FMTC) or be associated with
pheochromocytoma (PC) and parathyroid hyperplasia/neoplasia
(MEN 2A) or with PC, neuromas and body dimorphisms (MEN
2B). Germline mutations of the proto-oncogene RET confer
predisposition to all forms of familial MTC. The mutations fall
into two main groups (Kouvaraki et al., 2005): (a) Those affecting
the extracellular domain: These primarily involve cysteine residues
609, 611, 618 and 620 (exon 10), and 634 (exon 11). (b) Those
affecting the RET-TK domain: These primarily involve codons
768, 790 and 791 (exon 13), 804 (exon 14), 883 and 891 (exon 15),
and 918 (exon 16).
MEN 2A is associated mainly with germline mutations in the
extracellular cysteine-rich region involving codons 609, 611, 618
and 620 (exon 10), and codon 634 (exon 11; 31–32). In particular,
the Cys634Arg mutation speciﬁcally correlates with a higher risk
of hyperparathyroidism (Mulligan et al., 1994). Rare mutations
that are more commonly associated with MEN 2A include those
at codons 768, 790 and 791 (exon 13), 804 (exon 14), and 891 (exon
15; Kouvaraki et al., 2005; Evans et al., 2007). MEN 2B is caused
exclusively by mutations of residues within the intracellular TK
domain of the receptor. Almost 95% of cases have a Met918Thr
substitution (exon 16; Eng et al., 1996), and 3–4% are associated
with Ala883Phe (exon 15; Gimm et al., 1997; Smith et al., 1997).
Germline mutations in FMTC kindreds are more equally distrib-
uted throughout theRET gene and show a large overlapwith those
detected in MEN 2A (Kouvaraki et al., 2005; Evans et al., 2007).
All point mutations of RET in MEN 2 subjects are believed to
have a“gain-of-function”effect resulting in unregulated activation
of the TK activity of the receptor.
Mutations affecting cysteine residues in the extracellular
domain are thought to result in ligand-independent receptor
dimerization (Santoro et al., 1995; Carlomagno et al., 1997; Ito
et al., 1997; Chappuis-Flament et al., 1998). It is likely that the
cysteine residues normally form intramolecular disulﬁde bridges.
Substitution of one partner cysteine by another aminoacid results
in an unpaired cysteine, which is thought to link with its counter-
part in an adjacent molecule. This event mimics conformational
changes induced by ligand binding (Santoro et al., 1995).However,
signaling of MEN 2A RET mutant is not identical to ligand-
mediated RET signaling, as qualitative differences were identiﬁed,
i.e., in the activation of the PI3K/AKT pathway (Frêche et al.,
2005).
Mutations in the TK domain of RET constitutively activate the
receptor without a requirement for dimerization. This phenom-
enon might be linked to the fact that some of the intracellular
TK mutations target positions close to the trans-inhibited dimer
contact points and may activate RET by destabilizing this inactive
dimer conformation (Knowles et al., 2006). Moreover, the most
frequent MEN 2B mutation (Met918Thr) was found to cause
a great increase in ATP binding afﬁnity and the formation of
a more stable RET-ATP complex (Gujral et al., 2006). In addi-
tion to inducing“quantitative” changes of the basal kinase activity,
the Met918Thr mutation is thought to affect also the “quality” of
RET-generated intracellular signals by altering the afﬁnity of the
receptor to downstream substrates (Santoro et al., 1999).
Sporadic MTCs have no detectable germline abnormalities
in RET. However, a signiﬁcant proportion of these cancers has
acquired a mutation in RET as a somatic event during the course
of tumor initiation or progression (Romei et al., 1996; Elisei
et al., 2008). Here, the mutation is present only in the tumor,
and most often involves codon 918 (Met918Thr), although other
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RET mutations have also been reported, such as some at codons
634 and 883. Estimates of prevalence of somatic RET mutations
in sporadic MTC range from 23 to 70%. There are indications that
tumors harboring RET mutations may carry a worse prognosis
(Elisei et al., 2008).
The importance of RET mutations in the pathogenesis of either
familial or sporadic MTCs has triggered the development of RET
kinase inhibitors to be used in the clinical setting. At least four
small molecules reached speciﬁc clinical trials in patients with
unresectable, locally advanced or metastatic MTC: motesanib,
vandetanib, cabozantinib, and lenvatinib (Puxeddu et al., 2011).
Motesanib was tested in a multicenter phase II study which
enrolled 91 patients with advanced MTC (Schlumberger et al.,
2009). The study yielded an objective response rate of only 2%,but
a disease control rate (objective responses+ stable disease) of 83%,
with amedianprogression-free survival of 48weeks and acceptable
side effects. Compared to the very poor results of chemotherapy,
these data appeared very promising.Unfortunately, further clinical
development of motesanib was interrupted.
Vandetanib was tested in two phase II intervention studies
(administering 300 and 100mg per day, respectively) in patients
with locally advanced or metastatic familial MTC (Robinson et al.,
2010; Wells et al., 2010). Both studies showed objective responses
in about 20% of subjects and stable disease in about another
50%, with no signiﬁcant differences between the two dosages of
the drug. In the 300mg study median progression-free survival
was longer than 27 months. An international, phase III, ran-
domized, double-blinded, placebo-controlled, multicenter study
to assess the efﬁcacy of vandetanib vs. placebo in subjects with
unresectable, locally advanced or metastatic MTC was recently
completed (331 enrollments). The study met its primary objective
of signiﬁcant progression-free survival prolongation with van-
detanib vs. placebo (22.6 vs 16.4 months. H.R. 0.45, 95% C.I.
0.30–0.69, P = 0.0001) (Wells et al., 2012), prompting FDA to
approve the use of vandetanib to treat adult patients with late-
stage (metastatic) MTC who are ineligible for surgery and who
have disease that is growing or causing symptoms.
Cabozantinib was tested in a phase I dose-ﬁnding study which
enrolled patients with various cancers, including an expansion
cohort of 37 MTCs, showing some degree of tumor shrinkage in
almost all patients of the latter group with 29% qualifying for a
conﬁrmed PR (Kurzrock et al., 2011). The good results obtained
in the phase I study prompted the initiation of a registration
phase III, randomized, double-blinded, placebo-controlled trial
to determine the efﬁcacy of the drug against placebo in advanced
MTC patient, which is still ongoing2. Similarly, clinical efﬁcacy of
lenvantinib in advanced MTCs is tested in an ongoing phase II
study (see text footnote 2).
Interestingly, all this drugs are multikinase inhibitors whose
mechanism of action does not rely only on targeting RET, but
also VEGF receptors and receptors for other angiogenic factors
(PDGFRβ, c-KIT, c-MET) or growth factors (EGFR; Puxeddu
et al., 2011). Vendetanib has been demonstrated, and the other
considered TKI are expected, to inhibit also RET/PTCs and thus
2http://clinicaltrials.gov/
to represent speciﬁc targeted therapies also for PTC harboring this
class of gene rearrangements.
PREVALENCE OF RET/PTC REARRANGEMENTS
The prevalence of RET/PTC in PTCs varies signiﬁcantly in dif-
ferent studies and geographic regions (Nikiforov, 2002). In the
United States, the ﬁve largest series reported a frequency of
RET /PTC ranging from 11 to 43% (Jhiang et al., 1992; Santoro
et al., 1992; Lam et al., 1998; Tallini et al., 1998; Nikiforova et al.,
2002), with totally 134 positive cases among 386 PTCs cumu-
latively studied (mean prevalence 35%). A comparable rate has
been reported by other groups: Canada 40% (Sugg et al., 1999),
Italy 29–35% (Santoro et al., 1992; Bongarzone et al., 1996, 1998).
In other regions, a wide variation in frequency of RET/PTC has
been reported, ranging from 3% in Saudi Arabia (Zou et al.,
1994) to 85% in Australia (Learoyd et al., 1998). In most series,
RET/PTC1 is the most common type, comprising up to 60–70%
of all rearrangements, whereas RET/PTC3 accounts for 20–30%
of positive cases and RET/PTC2 for less than 10% (Nikiforov,
2002).
Several studies reported a higher prevalence of RET/PTC in
PTCs from children and young adults (Bongarzone et al., 1996;
Nikiforov et al., 1997; Soares et al., 1998; Fenton et al., 2000),
indicating that young age predisposes to the formation of these
mutations. Rapid thyroid cell proliferation may account for the
particular high sensitivity of children’s thyroids to chromosomal
recombinations (Saad et al., 2006). In all studies RET/PTC1 was
the major type of rearrangement.
Finally, the prevalence of RET/PTCs appeared signiﬁcantly
higher in PTC from patients with a history of radiation exposure
during childhood (Nikiforov,2002). TheChernobyl nuclear power
plant accident inApril 1986 resulted in the release of large amounts
of iodine isotopes, mainly 131I, and, therefore, there was wide-
spread exposure to the thyroid (Williams, 2002). A high incidence
of childhood PTC was reported in contaminated areas (Figure 6).
Among these PTCs, 67–87% of tumors removed 5–8 years after
exposure and 49–65% of those removed 7–11 years after the acci-
dent harbored RET/PTC (Fugazzola et al., 1995; Nikiforov et al.,
1997; Smida et al., 1999; Rabes et al., 2000). Interestingly, in post-
Chernobyl tumors developed less than 10 years after the accident,
RET/PTC3 appeared to be the most common type, whereas those
removed after the longer latency had predominantly RET/PTC1
(Smida et al., 1999; Rabes et al., 2000). In patients subjected to
therapeutic external irradiation during childhood the prevalence
of RET/PTC was also high ranging between 54 and 84% (Bounacer
et al., 1997; Elisei et al., 2001). In these cases RET/PTC1 was more
represented. However, exposure to ionizing radiations promotes
the fusion of RET also with unusual partners and it is in this
group that themajority of rare variants of RET/PTCs were detected
(Nikiforov, 2002).
Geographic variation and differences in radiation exposure
might partially explain the variability of RET/PTC frequencies
in the different studies (Zhu et al., 2006). However, this can-
not serve as the only explanation, because a striking variability
in the frequency has been reported in the same geographical
regions [8 and 85% in Australia (Learoyd et al., 1998; Chua
et al., 2000), 5 and 77% in Canada (Sugg et al., 1996, 1998)].
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FIGURE 6 | Effects of the Chernobyl accident. (A)The Chernobyl nuclear
power plant accident on April 26th 1986 resulted in the release of large
amounts of iodine isotopes, mainly 131I, that contaminated the ground of
surrounding regions, specially Belarus, with widespread exposure of the
thyroids of the inhabitants. A high incidence of childhood PTC was
reported in the more heavily contaminated areas (in the map small
numbers indicate the incidence of pediatric thyroid cancers in the different
districts of Belarus, reported as number of cases per 100,000 children)
[From Balter (1996) with permission of the American Association for the
Advancement of Science]. (B) Unexpectedly, after the accident a rise of
pediatric thyroid carcinomas was observed in Belarus with a latency as
short as 4 years. The highest price was payed by the younger children at
the time of the disaster [modiﬁed from Bleuer et al. (1997) with
permission of Alphamed Press, INC.].
Thus, it is conceivable that the discrepancy between the reported
prevalence of RET/PTC in PTCs may also be a result of dif-
ferent sensitivities of the detection methods and tumor genetic
heterogeneity (Zhu et al., 2006). In the ﬁrst instance, it has been
clearly demonstrated that efﬁcacy of RET/PTC detection, and of
consequent reported prevalence, changed using various reverse
transcriptase (RT)-PCR methods, or Southern blot, or ﬂuores-
cence in situ hybridization (FISH). In the second instance, it
has been clearly demonstrated that PTC can harbor RET/PTC
rearrangement either as a clonal mutation, affecting the major-
ity of tumor cells, or as a “non-clonal” one, affecting a small
portion of tumor cells (Rhoden et al., 2006; Zhu et al., 2006).
In the ﬁrst case the genetic modiﬁcation is likely to be impor-
tant for tumor formation, in the second one the mutation
might represent only a casual alteration with no impact on the
cancerogenetic process (“passenger mutation”). A counting of the
second group in the RET/PTC-positive cases leads to an overes-
timation of the frequency of the mutation and to the inclusion
of heterogeneous cases in the group of tumors driven by RET
rearrangements.
The presence of RET/PTC rearrangements in non-neoplastic
cells in Hashimoto’s thyroiditis is still controversial. It is possible
that a heterogeneous presence of the rearrangement may account
for such a controversy (Tallini and Asa, 2001; Nikiforov, 2002;
Rhoden et al., 2006).
Tumor heterogeneity and multiclonality is also indicated by the
presence of multiple RET/PTC variants in individual PTC samples
(Sugg et al., 1998).
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Among thyroid lesions, RET/PTC rearrangements have so far
been identiﬁedonly inPTC.They are absent in follicular adenomas
and follicular thyroid carcinomas (Santoro et al., 2006).
In PTC, they are more frequent in the classic variant (Adeni-
ran et al., 2006) and in microcarcinomas (Fusco et al., 2002),
although they have been rarely described also in the cribriform
variant (Cetta et al., 1998), in the Huerthle cell variant (Cheung
et al., 2000; Chiappetta et al., 2002) and in hylinazing trabecular
adenomas (Cheung et al., 2000; Papotti et al., 2000). In radiation-
induced PTC the solid variant is associated with the RET/PTC3
oncogene,whereas the classic variant is associated with RET/PTC1
(Nikiforov et al., 1997).
There is some controversy on the occurrence of RET/PTC
rearrangements in poorly differentiated (PDTC) and anaplastic
thyroid carcinomas (ATC) which are believed to derive in a sig-
niﬁcant number of cases from a stepwise dedifferentiation of
well-differentiated PTCs and follicular thyroid carcinomas (Jhi-
ang et al., 1992; Bongarzone et al., 1998; Soares et al., 1998;
Tallini et al., 1998; Nikiforov, 2004). A recent study analyzed the
mutational proﬁle of advanced thyroid carcinomas of follicular
origin, including primary PDTC and ATC and RAI refractory-
FDG-PET positive-metastatic thyroid cancer lesions (Ricarte-
Filho et al., 2009). It revealed that 18% of PDTC and 9% of
RAI refractory-FDG-PET positive-PDTC harbored a RET/PTC
rearrangement.
MECHANISMS OF RET/PTC FORMATION
As mentioned above, thyroid cancer, and in particular PTC, fre-
quently harbor chromosomal rearrangements, including intra-
chromosomal inversions and inter-chromosomal translocations.
In all rearrangements, the formation of breaks in DNA strands
must occur. There are various ways in which a cell can acquire
these breaks, but exposure to ionizing radiation represents the
best known mode (Weterings and Chen, 2008). DNA breaks are
commonly repaired by two pathways, homologous recombination
or non-homologous end joining (NHEJ; Shrivastav et al., 2008),
and dysfunction of these pathways can contribute to the formation
of chromosomal translocations (Gasparini et al., 2007). Alterna-
tively, a fulsome accumulation of DNA breaks could prevent these
normally functioning repair mechanisms, leading to translocation
events.
Chromosomal fragile sites are regions of the genome that
are prone to DNA breakage and are hotspots for chromosomal
translocations. They are classiﬁed as common and rare, depend-
ing on their frequency in the population. Common fragile sites
can be further classiﬁed based on their mode of induction, as not
all sites are induced by the same compounds, or to the same extent.
Aphidicolin (APH) induces expression of themajority of common
fragile sites; other known fragile site-inducing conditions are the
addition of 5-bromodeoxyuridine (BrdU), 5-azacytidin, and the
removal of folic acid (Sutherland, 1991). Moreover, certain dietary
and environmental factors have been shown to contribute to frag-
ile site expression, including caffeine (Yunis and Soreng, 1984),
ethanol (Kuwano and Kajii, 1987), hypoxia (Coquelle et al., 1998),
and pesticides (Musio and Sbrana, 1997).
Fragile sites are also known to be late replicating regions of the
genome. Delayed DNA replication has been observed in all fragile
sites examined to date (Handt et al., 2000; Hellman et al., 2000;
Palakodeti et al., 2004; Pelliccia et al., 2008). Delayed replication
at fragile sites is believed to be attributed to the high propensity of
DNA to form stable secondary DNA structures (Gacy et al., 1995;
Usdin and Woodford, 1995; Hewett et al., 1998; Mishmar et al.,
1998; Zlotorynski et al., 2003; Zhang and Freudenreich, 2007).
Many studies point toward the association between fragile
sites and formation of cancer-speciﬁc translocation (Arlt et al.,
2006). Genes participating in the two main types of RET/PTC
rearrangements, RET/PTC1 and RET/PTC3, have been mapped
to known fragile sites (Burrow et al., 2009). Both genes involved
in the RET/PTC3 rearrangement, RET and NCOA4, are located at
10q11.2 within fragile site FRA10G, a common fragile site induced
by APH. The CCDC6 gene, involved in RET/PTC1, is located at
10q21.2 within fragile site FRA10C, a common fragile site induced
by BrdU. Major breakpoint cluster regions for these genes have
been identiﬁed and are located within intron 11 of RET, intron 5
of NCOA4 and intron 1 of CCDC6 (Smanik et al., 1995; Nikiforov
et al., 1999).
In a recent study, Gandhi and others showed the involve-
ment of fragile sites in the formation of RET/PTC rearrange-
ments. Using FISH and ligation-mediated PCR (LM-PCR) analy-
sis, they provided structural and biochemical evidence that the
RET, CCDC6, and NCOA4 genes are located in common frag-
ile sites FRA10C and FRA10G and undergo DNA breakage after
exposure to fragile site-inducing chemicals. Moreover, exposure
of human thyroid cells to these chemicals results in the forma-
tion of cancer-speciﬁc RET/PTC rearrangements (Gandhi et al.,
2010). These results provide the direct evidence for the involve-
ment of chromosomal fragile sites in the generation of cancer-
speciﬁc rearrangements in human cells. In particular, activation of
FRA10C and FRA10Gmight contribute to spontaneous formation
of RET/PTC1 andRET/PTC3 rearrangements leading to the devel-
opment of spontaneous non-radiation induced PTCs harboring
the rearrangements.
Exposure to ionizing radiation is a well known risk factor for
thyroid cancer, especially for PTC,which represents themost com-
mon form of radiation-induced solid neoplasm (Winship and
Rosvoll, 1970; Ron et al., 1995). As reported above, a high preva-
lence of RET/PTC is seen in PTCs of individuals with a history
of radiation exposure (Bounacer et al., 1997; Nikiforov et al.,
1997; Rabes et al., 2000; Elisei et al., 2001). Moreover, among
PTCs of survivors of the atomic bomb in Japan, the presence
of RET/PTC directly correlated with the received radiation dose
(Takahashi et al., 2007; Hamatani et al., 2008). The association
between RET/PTC rearrangement formation and ionizing radia-
tion is supported by several studies demonstrating the induction
of RET/PTC by irradiation of cultured human thyroid cells (Ito
et al., 1993; Caudill et al., 2005) and of human fetal thyroid tissue
xenografts in SCID mice (Mizuno et al., 1997, 2000).
Ionizing radiation damages DNA in a variety of ways as a
result of either direct energy transfer by radiation to DNA or
by secondary reactive oxygen species produced by ionization of
water. Of all types of DNA damage, double-strand breaks (DSBs)
are considered a crucial primary lesion for a variety of biologi-
cal end points, including cell killing, chromosomal aberrations,
and cell transformation (Bryant and Riches, 1989; Winegar et al.,
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1992). However, exactly how radiogenic DSBs lead to chromoso-
mal rearrangements remains not fully understood. Several theories
have been proposed but none of these can adequately explain
the dose–effect relationship and complexity of radiation-induced
aberrations (Edwards, 2002). The most widely accepted theory
is the Breakage-and-Reunion theory. It postulates that chromo-
somal aberrations arise mainly as a result of the re-joining of
two DSBs located closely in space and time (two-hit event; Sav-
age, 1998; Hlatky et al., 2002). The initial distribution of primary
breaks is thought to be random whereas the rejoining efﬁciency is
expected to be inﬂuenced by their proximity (Yates and Morgan,
1993; Rothkamm et al., 2001).
It seems that nuclear architecture contributes to the generation
of RET/PTC by placing potentially recombinogenic chromosomal
loci in close proximity in the interphase nuclei of human cells.
In a study that utilized FISH and three-dimensional (3D) confo-
cal microscopy, it was demonstrated that RET and CCDC6 genes,
the partners of RET/PTC1 rearrangement, were non-randomly
located with respect to each other in the interphase nuclei of
human thyroid cells and were much closer than expected based on
their genomic separation (Nikiforova et al., 2000; Figures 7A–C).
Moreover, this study showed that the proximity between poten-
tially recombinogenic genes was cell-type speciﬁc and was present
only in thyroid cells. In a more recent study, similar ﬁndings
were obtained for RET and NCOA4, the partners of RET/PTC3
rearrangement (Gandhi et al., 2006;(Figures 7D–E).
In mammalian cells, DSBs are repaired by two pathways
that are based on homologous or non-homologous recombina-
tion. The homology-dependent mechanism encompasses homol-
ogous recombination repair (HRR), single strand annealing (SSA),
and non-allelic homologous recombination (NAHR). The non-
homologous mechanism is known as non-homologous end join-
ing (NHEJ). Another recently found repair pathway, micro-
homology mediated end joining (MMEJ), combines features of
the major pathways as it joins DNA ends after preliminary align-
ment using short homology DNA sequences located distant from
the break.
Data obtained by the analysis of DNA sequences at the fusion
points suggest that the formation of RET/PTC rearrangements
may involve several possible DNA repair mechanisms, particularly
NHEJ andMMEJ,and to lesser extent SSA (Bongarzone et al., 1997;
Klugbauer et al., 2001). It remains unclear if all these pathways con-
tribute to the generation of RET/PTC with similar frequency and
if the choice is determined by speciﬁc conditions and/or individual
genetic background.
Regardless of the speciﬁc DNA repair mechanism involved in
recombination, spatial proximity is likely to predispose to spe-
ciﬁc rearrangements by making the neighboring regions prone
to simultaneous damage by radiation or other DNA-damaging
agents, and/or by facilitating mis-rejoining of free DNA ends
located closely adjacent to each other (Figure 7F).
It remains unclear why speciﬁc chromosomal regions are
located close to each other. For genetic loci located on the same
chromosome, this is likely due to high order chromosome folding
that would allow the genes to be positioned non-randomly with
respect to each other. It has been found that the 18-Mb region on
FIGURE 7 | Proximity of chromosomal loci that participate in RET/PTC
rearrangements. (A) Fluorescence in situ hybridization (FISH) analysis of
the distance between RET and H4/CCDC6 loci within interphase nuclei
showed that, despite a linear distance of 18Mb, at least one pair of RET
and H4/CCDC6 was juxtaposed in 35% of normal human thyroid cells (right
panel). Conversely, the set of numbers obtained measuring the distance
between RET and the control locus D10S539 ﬁtted with the expected
Rayleigh distribution (left panel; from Nikiforova et al. (2000) with
permission of the American Association for the Advancement of Science).
(B) 2D image of three-color FISH showing positioning of RET (green),
(Continued)
www.frontiersin.org May 2012 | Volume 3 | Article 67 | 9
Menicali et al. Thyroid cell transformation by RET/PTC
FIGURE 7 | Continued
NCOA4 (orange), and H4/CCDC6 (red) in interphase nuclei of thyroid cells.
The panel depicts a nucleus showing two sets of RET, NCOA4, and
H4/CCDC6 with one pair of RET and H4/CCDC6 positioned close to each
other. (C) 3D image showing that RET and H4/CCDC6 are juxtaposed to
each other in the same z plane. (D) 2D image of a nucleus showing one pair
of RET and NCOA4 positioned close to each other. (E) 3D image showing
that RET and NCOA4 are juxtaposed to each other in the same z plane (B–E
are from Gandhi et al. (2010) with permission of Elsevier Ireland LTD). (F)
Spatial contiguity of RET and the fusion partner gene may provide a
structural basis for generation of RET/PTC rearrangement by allowing a
single radiation track to produce a double-strand break in each gene at the
same site in the nucleus (Nikiforova et al., 2000). (G) Four-color FISH
showing chromosome 10 territory (green) and location of RET (blue
pseudocolor), NCOA4 (yellow pseudocolor), and H4/CCDC6 (red). All three
genes, RET, NCOA4, and H4/CCDC6, are positioned within the
chromosome 10 territory (CT) and away from the CT edge. (H) 3D rendered
image showing no signals on the surface of the CT due to the gene
positioning inside the CT. (G–H are from Gandhi et al. (2010) with
permission of Elsevier Ireland LTD).
10q containing RET, NCOA4, and CCDC6 has a large-scale heli-
cal folding in the interphase nuclei of human thyroid cells. This
pattern of chromatin folding can offer the basis for the proximity
between RET and NCOA4 and CCDC6 (Gandhi et al., 2006).
A particular feature of rearrangements found in papillary thy-
roid cancers is that almost all of them are intra-chromosomal
inversions rather than inter-chromosomal translocations; thismay
be due in part to the nuclear architecture. It was found that genes
involved in intra-chromosomal rearrangements were positioned
at signiﬁcantly greater distances away from the chromosomal ter-
ritory (CT) edge and internally within their CTs as compared to
genes involved in translocations that were positioned closer to the
CT edge (Gandhi et al., 2009). The frequent location of RET and its
recombinogenic partners within the interior of CT and the limited
availability of it to interact with neighboring chromosomal terri-
tories likely predispose it to intra-chromosomal inversions, such
as that seen in most cases of RET/PTC (Figures 7G–H).
SIGNALING PATHWAYS ACTIVATED BY RET/PTC
Several RET/PTC-activated signal transduction pathways have
been identiﬁed. In detail, RET/PTC signaling, as RET signaling,
depends on the auto-phosphorylation of several tyrosine residues
(Figure 8). Tyrosine (Y) 905 (numbered according to integral RET
amino acid sequence) is a binding site for Grb7/10 adaptors whose
function has not been completely elucidated (Wells and Santoro,
2009). Y905 is also a binding site for SH2B1β, a protein that, by
obstructing the SHP-1 tyrosine phosphatase, enhances RET phos-
phorylation (Donatello et al., 2007). Y1015 interacts with phos-
pholipase Cγ, thereby activating protein kinase C enzymes, which
in turn are key regulators of receptor TKs (Andreozzi et al., 2003).
Y1062 is a highly important multi-docking binding site for several
signalingmediators such asDOK1/4/5,Enigma,FRS2, IRS1/2, Shc,
and ShcC. Phosphorylation of tyrosine 1062 results in the acti-
vation of major intracellular mediators, including ERK/MAPK,
PI3K-AKT, NF-kB, and JNK (Wells and Santoro, 2009). Y1062-
mediatedMAPKactivation appears to happen through theDOK4-
Rap1 signaling cascade (Uchida et al., 2006; De Falco et al., 2007).
Y1062 is essential for RET and RET/PTC transforming activity
(Segoufﬁn-Cariou and Billaud, 2000; Knauf et al., 2003; Melillo
et al., 2005). Y1096, present only in the RET51 splicing variant,
binds Grb2 and appears to have a redundant behavior with Y1062
on the activation of the AKT/MAPK pathways (Jain et al., 2006).
Y752 and Y928 of MEN2A-RET appeared to be YxxV/Q Sig-
nal Transducer and Activator of Transcription 3 (STAT3) docking
sites, involved in MEN2A-RET-induced phosphorylation of both
Y705 and S727 residues of STAT3 (Schuringa et al., 2001). More
recently, it was shown that RET/PTC1 and RET/PTC3 also inter-
act with STAT3 and activate it through the phosphorylation of the
tyrosine 705 residue (Hwang et al., 2003). However, RET/PTC1
residues Y141 and Y317, corresponding to RET residues Y752 and
Y928, respectively, did not appear to be critical for the interac-
tion with the transcription factor. Conversely, Y317 of RET/PTC1
appeared to be important for auto-phosphorylation of the kinase
and for the Y705 phosphorylation of STAT3. This phosphory-
lation event appeared to require the intrinsic kinase activity of
RET/PTC and to be independent from JAK2 and c-Src activation
conﬁrming that STAT3 is a direct substrate of RET/PTCTK in vivo.
A physical interaction between RET/PTCs and the transcription
factor could be demonstrated by co-immunoprecipitation exper-
iments. Similarly, the expression of RET/PTC was found to lead
to up-regulation of STAT1 expression and to the phosphoryla-
tion of the Y701 residue of this transcription factor (Hwang et al.,
2004). Also in this case the dependence of the phosphorylation
event from RET/PTC intrinsic kinase activity and its indepen-
dence from JAKs and c-Src kinases activation pointed to the direct
interaction between RET/PTCs and STAT1, although the occur-
rence of an association between RET/PTC and STAT1 could not
be demonstrated by immune-precipitation analysis.
Among the non-phosphotyrosine mechanisms involved in
RET/PTC signaling, binding of the PDZ-containing scaffold pro-
tein Shank3 to the C-tail of the RET9 splicing variant should
be recalled. It contributes to sustained ERK and PI3K signaling
(Schuetz et al., 2004).
Very recently, it was shown that RET/PTCs activate at least
part of their pro-inﬂammatory programs through associationwith
TRAF2 and TRAF6 which in turn activate NF-kB by inhibiting
the constitutive proteolytic degradation of NIK kinase. This pro-
inﬂammatory signaling pathway appeared to be independent from
PI3K/AKT and RAS/BRAF/MEK/ERK pathways. Thus, the possi-
bility was proposed that RAS/BRAF and/or PI3K/AKT pathways
are required for cellular transformation and that the additional
pro-inﬂammatory pathways of RET/PTCs shape the features of
the growing tumor (Wixted et al., 2011).
GENE EXPRESSION MODIFICATIONS INDUCED BY RET/PTCs
IN CELLULAR MODELS
Gene expression modiﬁcation induced by RET/PTCs has been
studied principally and more consistently in cellular models.
A microarray analysis was conducted on well differentiated rat
thyroid PCCL3 cells conditionally expressing theRET/PTC3 onco-
gene. Gene expression proﬁling 48 h after activation of RET/PTC3
identiﬁed a statistically signiﬁcant modiﬁcation of expression of
270 genes. Functional clustering of genes with a signiﬁcant expres-
sion change revealed RET/PTC3-induced regulation of genes
with key functions in apoptosis (Ripk3, Tdga), cell–cell signaling
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FIGURE 8 | Signal transduction pathways regulated by RET/PTCs.Tyrosine residues (Y) are numbered according to integral RET amino acid sequence. RET9
and RET51 represent splicing variants of RET C-terminal tail.
(Cdh6, Fn1), cell cycle (Il24), immune and inﬂammatory response
(Cxcl10, Scya2, Il6, Gbp2, Oas1, Tap1, RT1Aw2, C2ta, Irf1, Lmp2,
Psme2, Prkr), metabolism (Aldob, Ptges, Nd2, Gss, Gstt1), signal
transduction (Socs3, Nf1, Jak2, Cpg21, Dusp6, Socs1, Stat1, Stat3,
Cish), and transcription (Nr4a1, Junb, Hfh1, Runx1, Foxe1). This
study clearly showed that genes coding for proteins involved in
the immune response and in intracellular signal transduction
pathways activated by cytokines and chemokines were strongly
represented, indicating a critical role of RET/PTC3 in the activa-
tion and modulation of immune and inﬂammatory responses to
the tumor (Figure 9) (Puxeddu et al., 2005a). The likely mediators
of these expression clusters are NF-kB, STAT1, and STAT3, based
on data from the microarray and the literature (Hwang et al.,
2003, 2004; Wixted et al., 2011) and preliminary data from our
laboratory.
Similarly, exogenous expression of RET/PTC1 in primary
normal human thyrocytes induced the expression of a set of
genes involved in inﬂammatory/immune response including those
encoding chemokines (CCL2, CCL20, CXCL8, and CXCL12),
chemokine receptors (CXCR4) and cytokines (IL1B, CSF-1, GM-
CSF, and G-CSF). Moreover, the modulation of genes involved
in tumor invasion could be demonstrated, including matrix-
degrading enzymes (metalloproteases and urokinase-type plas-
minogen activator and its receptor), and adhesion molecules
(L-selectin). All these effects were strictly dependent on the pres-
ence of the RET/PTC1 Y451 residue (corresponding to RET
Y1062 multidocking site). Selected relevant genes (CCL20, CCL2,
CXCL8, CXCR4, L-selectin, GM-CSF, IL1B, MMP9, UPA, and
SPP1/OPN ) were found up-regulated also in clinical samples of
PTC, particularly those characterized by RET /PTC activation,
local extrathyroid spread, and lymph node metastases (Borrello
et al., 2005).
Another study analyzed the gene expression proﬁle of the TPC1
cell line, derived from a papillary thyroid cancer lymph node
metastasis and naturally harboring a RET/PTC1 rearrangement,
andof the thyroid follicular cell lineNthy-ori 3-1 stably transduced
with the oncogene. Among the genes found to be overexpressed,
those involved in biological processes such as cell differentia-
tion, proliferation, and cell signaling were over-represented. Such
genes included CEBPB, CCNG1, IFITM3, HTRA1, SEMA3F, and
P300/CBP-associated factor (PCAF). Among the genes shown to
be down-regulated in RET/PTC1-expressing cell lines when com-
pared to normal control, those involved in cell structure and
motility, cytoskeletal remodeling, and cell signaling were over-
represented. Examples of such genes included DCTN5, TPM1,
TPM3, CRP1, Keratin type 1, Tropomyosin, PSMD2 (TRAP2),
and RAB32. Of particular interest in this study was the discov-
ery of the under-expression of DROSHA in PTC cell lines. This
is the core nuclease that executes the initiation step of miRNA
processing in the nucleus. DROSHA collaborates with Dicer in
stepwise processing of miRNAs and has a key role in miRNA
mediated gene regulation processes such as development and dif-
ferentiation. Interestingly, evaluation of the miRNA expression
proﬁle in the same cell lines revealed 21 overexpressed miRNAs
and 14 underexpressed miRNAs in both cell lines when com-
pared to Nthy-ori 3-1. Thus, miRNAs expression also appeared
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FIGURE 9 | Schematic map of the relationships between RET/PTC3
and IFN- and cytokine-activated signal transduction pathways
according to the microarray results and to the literature. Up-regulated
genes are shaded, whereas black dots indicate activation by
phosphorylation. RET/PTC3 induces the expression of STAT1 and STAT3,
involved respectively in the regulation of IFN and cytokine (e.g., IL-6) signal
transduction pathways. RET/PTC3 also activates both transcription factors
through direct phosphorylation of critical tyrosine residues (Hwang et al.,
2003, 2004) and through increased IL-6 expression, possibly via NF-kB
(Wixted et al., 2011) (STAT3 activation). In addition RET/PTC3 induces the
expression of additional components of these two pathways, such as
JAK2, SOCS1 and 3, CISH and PTPRN. RET/PTC3-induced activation of
STAT1 results in the up-regulation of IFN-responsive genes, whereas
activation of STAT3 results in the up-regulation of VEGF, Cyclin D1, and
ICAM (Hwang et al., 2003; modiﬁed from Puxeddu et al. (2005a) with
permission of Bioscientiﬁca Limited).
to be signiﬁcantly affected by RET/PTC1 expression (Cahill et al.,
2006).
Another study compared the transformed phenotype and the
gene expression proﬁle of rat thyroid PCCL3 cells stably expressing
RET/PTC3 and its mutant RET/PTC3(Y1062F), BRAF(V600E),
and H-RAS(V12). In the ﬁrst instance, the authors could demon-
strate that the oncogenic proteins involved in the initiation of PTC
work along the same signaling cascade. This pathway starts at the
level of RET tyrosine 1062 and sequentially triggers RAS, BRAF,
and ERK stimulation. However, the analysis of transcriptional
proﬁles indicated that the three oncoproteins are not completely
equivalent. Indeed, in addition to targets common to RET/PTC3,
HRAS, and BRAF, there were relatively large sets of genes speciﬁ-
cally modulated by only one or two of the three oncogenes. Many
of the commonly modulated genes were involved in hallmarks of
neoplastic transformation, e.g., altered cell morphology, uncon-
trolled growth, loss of differentiation, and apoptosis. RET/PTC3-
induced genes included metalloproteinases (Mmp3, -10, -12, -13),
those encoding adhesion/structure-associated proteins, such as
collagen 1 (Col1α1), thymosinβ4, and galectin-3, and the dual-
speciﬁcity phosphatase Dusp6. Moreover, the RET/PTC-RAS-
BRAF signaling cascade appeared to stimulate the overexpression
of some chemokines/cytokines (Cxcl1, Cxcl10, and Ccl2). Thus,
this study too conﬁrmed a strict relationship between thyroid can-
cer and inﬂammation in which tumors appear to use molecules of
the innate immune system not only to recruit leukocytes, but also
for growth, survival, and metastasis (Melillo et al., 2005).
A ﬁnal study which evaluated RET/PTC3-induced gene expres-
sionproﬁle in a cellularmodelwas a follow-up studyof theﬁrst one
described in this paragraph (Puxeddu et al., 2005a). It compared
PCCL3 cells with conditional expression of RET/PTC3 to PCCL3
cells with conditional expression of BRAF(V600E) or RET/PTC3
in the presence of small interfering RNA-mediated knockdown
of BRAF. Among the RET/PTC3-induced genes, 2,552 did not
require BRAF as they were similarly regulated by RET/PTC3
with or without BRAF knockdown and not by expression of
BRAF(V600E). Acquired immune response and IFN-related genes
were highly represented in this group. Conversely, about 24% of
RET/PTC3-regulated genes were BRAF dependent, as they were
similarly modiﬁed by RET/PTC3 and BRAF(V600E) but not in
cells expressingRET/PTC3with knockdownof BRAF.A signiﬁcant
subset of genes involved in innate immune responses belong to
this group. Among them were the monocyte-macrophage chemo-
attractants Mcp1 (Ccl2), Mcp3, Gm-Csf, and Ccl15. Moreover, a
gene cluster coding for components of the mitochondrial elec-
tron transport chain pathway was down-regulated in this group,
potentially altering regulation of cell viability. Genes coding for
metalloproteinases were also preferentially induced by BRAF, par-
ticularly Mmp3, Mmp9, and Mmp13. This study recapitulated
most of the data reported by the previous ones indicating a fairly
clear demarcation between some of the functional gene programs
activated by RET/PTC3 and BRAF in thyroid cells. RET/PTC3
appeared to induce expression of a remarkably rich array of genes
involved in acquired immunity, whereas BRAF appeared to evoke
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expression of genes that promote activation of an innate immune
reaction. Moreover, although both genes induced expression of
genes involved inmatrix remodeling,RET/PTCdid so less robustly,
which could account in part for the lower predisposition of PTC
harboring RET/PTC rearrangements to invade surrounding tis-
sues compared to those harboring BRAF mutations (Mesa et al.,
2006).
INSIGHTS ON RET/PTC INFLUENCES ON TUMOR
MICROENVIRONMENT
RET/PTC oncoproteins are believed to take part in several mech-
anisms that allow tumor growth and spread, including angiogen-
esis, invasion, metastasis, and immune escape. RET/PTC induces
these signiﬁcant phenotypic changes oriented toward neoplastic
transformation affecting the tumor microenvironment.
Eicosanoids are thought to play an important role in sur-
vival, growth and metabolic support of tumor cells (Koki et al.,
2002). Signiﬁcant among them are prostaglandins, of which
prostaglandin E2 (PGE2) is the most abundant in nature. The
synthesis of PGE2 from arachidonic acid requires two enzymes
acting sequentially. The ﬁrst step is catalyzed by cyclooxygenase
(COX), which transforms arachidonic acid in the endoperox-
ide prostaglandin H2 (PGH2). The second step is catalyzed by
prostaglandin E synthase (PGES), which converts PGH2 in PGE2.
There are two COX isoforms: COX-1 and COX-2. COX-1 is con-
stitutively expressed in most tissues whereas COX-2 is normally
not expressed but is induced by growth factors, cytokines and
certain oncogenes (Smith and Langenbach, 2001). A variety of
epithelial cancers have increased expression of COX-2, including
colorectal (Eberhart et al., 1994; Yoshimatsu et al., 2001) and thy-
roid carcinomas (Nose et al., 2002; Specht et al., 2002). There
are three PGES isoforms: cytosolic PGES (cPGES), microsomal
PGES-1 (mPGES-1) and mPGES-2. cPGES is expressed consti-
tutively and has been proposed to exhibit preferential functional
coupling with COX-1 (Tanioka et al., 2000). mPGES-1 is induced
bypro-inﬂammatory stimuli and increases during theperiodwhen
COX-2-dependent PGE2 generation is ongoing (Murakami et al.,
2000; Mancini et al., 2001). mPGES-2 does not show homology
with mPGES-1 (Tanikawa et al., 2002) and has been proposed
to couple functionally to both COX-1 and COX-2 (Murakami
et al., 2003). mPGES-1 is overexpressed in most colorectal adeno-
mas and carcinomas, suggesting that this may contribute to the
increased amounts of PGE2 in these tumors.
Conditional expression of RET/PTC1 or RET/PTC3 in PCCL3
thyroid cells markedly induced both COX-2 and mPGES-
1 mRNA and protein. Accordingly, conditioned media of
these cells, analyzed by HPLC or ELISA, showed a signiﬁcant
increase of PGE2 concentration (Figure 10). Based on sig-
nal transduction dissection experiments, RET/PTC was found
to regulate mPGES-1 expression through the MAPK path-
way (Puxeddu et al., 2003a). These data indicate a direct
relationship between RET/PTC activation and regulation of
PGE2 synthesis. It can be speculated that paracrine action
of PGE2 might inﬂuence tumor development and progression
regulating angiogenesis and the anti-tumor immune response.
However, further investigation is needed to fully understand these
phenomena.
It has been hypothesized that the RET/PTC oncogene con-
tributes to tumor invasion. Castellone and others, explored the
transcriptional response of PCCL3 cells to RET/PTC oncogene
expression looking for the overexpression of genes involved in
tumor cell diffusion. They found that among several genes induced
by RET/PTC, CXCR4 showed approximately a threefold increase.
Western blot with anti-CXCR4 polyclonal antibody conﬁrmed
the overexpression of CXCR4 in rat transformed thyroid cells
(Castellone et al., 2004). CXCR4 is the receptor for the chemokine
CXCL12/SDF-1α/β. Chemokines are chemoattractant cytokines
that play a major role in the recruitment of leukocytes to sites of
inﬂammation. They are secreted in the tumor microenvironment
by inﬁltrating inﬂammatory cells and by tumor cells (Balkwill and
Mantovani, 2001; Coussens and Werb, 2002). Chemokines bind
to seven-transmembrane receptors present on the cell surface that
are coupled to G proteins, such as CXCR4, and activate a cascade
of cellular events that result in cell polarization, adhesion, and
migration (Melillo et al., 2005). Castellone and others observed
that CXCR4 expression correlated with the integrity of RET/PTC
catalytic domain and depended on the activation of the RET/PTC-
RAS-ERK signaling pathway. They also found that CXCR4 was
expressed in RET/PTC-positive human thyroid cancer cells but
not in normal thyroid cells. Treatment with SDF-1α caused an
increase of the proliferation and survival of PCCL3 cells expressing
RET/PTC1 (PC-PTC1 cells) and of Matrigel invasion of PC-PTC1
and human FB2 cells (PTC-derived cell line expressingRET/PTC1;
Castellone et al., 2004). Taken together, these results suggest that
human thyroid cancers harboring RET/PTC rearrangements may
use the CXCR4/SDF-1α receptor-ligand pathway to proliferate,
survive, and migrate.
Moreover, there are other reasonswhy the expression of CXCR4
in human PTCs could be important. In the ﬁrst instance, it might
contribute to the preferential localization of PTC metastases to
lymph nodes. Indeed, lymph nodes have been indicated as sites
of high production of SDF-1α (Müller et al., 2001). Moreover,
CXCR4 expression might enhance the tumor inﬂammatory inﬁl-
trate through the activation of signal transduction pathways that
lead to the secretion of cytokines. Indeed, it has been shown that
stimulation of CXCR4 in ovarian cancer leads to the production
of TNF-α, which, in turn, can behave as a growth factor for cancer
cells or mediate other events such as recruitment of leukocytes to
the tumor site (Scotton et al., 2002).
As already reported above, Melillo showed that RET/PTC3,
HRAS(V12), and BRAF(V600E) oncogenes activate a common
transcriptional program in thyroid cells that includes CXCL1/
growth-related oncogene-α (CXCL1/GRO-α) and CXCL10/
interferon-γ-inducible protein 10 (CXCL10/IP-10) chemokines.
According to the microarray results, QPCR data demonstrated
that CXCL1 and CXCL10 were up-regulated also in human PTCs.
CXCR2 (the CXCL1 receptor) and CXCR3 (the CXCL10 recep-
tor) were expressed in parental and transformed PCCL3 cells and
up-regulated in all the PTC cell lines examined in comparison
to normal thyroid follicular cells. Treatment of TPC1 cells with
recombinant CXCL1 and CXCL10 stimulated DNA synthesis and
cell invasiveness through Matrigel (Melillo et al., 2005).
These data are very interesting in light of the fact that at least
30% of PTC present a chronic inﬂammatory reaction (Rosai et al.,
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FIGURE 10 | RET/PTC3 regulates PGE2 biosynthesis in PCCL3 cells
characterized by the doxycycline (DOX)-inducible expression of the
oncogene (PTC3-5 cells). (A) Northern blots showing that treatment with
DOX for up to 96 h induces COX-2 and mPGES-1 mRNA but not COX-1,
mPGES-2, or cPGES. (B)Western blots conﬁrming that activation of
RET/PTC3 expression for up to 96 h induces COX-2 and mPGES-1 protein but
not COX-1, mPGES-2, or cPGES. (C) HPLC analysis of conditioned medium of
PTC3-5 cells metabolically labeled with [3H]arachidonic acid showing that
doxycycline (DOX) treatment induces PGE2 synthesis and secretion in the
medium [modiﬁed from Puxeddu et al. (2003a)].
1992; Scarpino et al., 2000). A molecular explanation of this phe-
nomenon could be the fact that the RET/PTC-RAS-BRAF signal-
ing cascade stimulates the overexpression of several chemokines.
In turn, chemokines secreted by cancer cells can recruit leukocytes
to the tumor site (Luster, 1998; Mellado et al., 2001). Moreover, it
can be envisaged that these chemokines secreted by the cancer cells
in the tumor microenvironment can act in an autocrine/paracrine
fashion to support proliferation and cell motility of cancer cells
themselves.
By using PCCL3 cells, osteopontin (OPN) has been identiﬁed
as a major transcriptional target of RET/PTC in thyroid cells.
OPN, also known as SPP1 (secreted phosphoprotein 1) is a highly
acidic calcium-binding glycosylated phosphoprotein that binds
to the cell surface receptors αv- or β1-containing integrins and
CD44 (Weber, 2001). It is also regarded as a cytokine (ETA-1,
Early T-lymphocyte antigen, or IL-28) regulating T helper cell-1
function (Ashkar et al., 2000; Chabas et al., 2001). OPN supports
several functions including chemotaxis, cell attachment, and cell
migration; involvement of OPN in tumorigenesis and metastasis
formation has elicited much interest (Weber, 2001).
CD44 is a cell surface glycoprotein that can be expressed
as a standard receptor (CD44s) or as multiple splice isoforms
(CD44v) whose expression is altered during tumor growth and
progression. Expression of the v6 exon variant is necessary for
efﬁcient OPN binding (Weber, 2001; Ponta et al., 2003). Normally,
only CD44s is expressed on the cell surface of non-proliferating
thyrocytes, whereas CD44v6 is invariably overexpressed in PTC
samples (Ermak et al., 1996; Bartolazzi et al., 2001). CD44 has been
implicated in cell–cell and cell–matrix interactions and homing of
tumor cell metastasis (Ponta et al., 2003).
OPN is expressed in several human tumors, such as colon,
breast, prostate, ovarian, gastric, and lung carcinomas. More-
over, OPN expression often correlates with a poor prognosis
(Rittling and Chambers, 2004). It has been shown that OPN
produced by RET/PTC-transformed thyrocytes cooperates with
RET/PTC to increase DNA synthesis and invasiveness of PCCL3
cells (Castellone et al., 2004).
In a more recent work, OPN and CD44 expression were eval-
uated by immunohistochemistry with speciﬁc monoclonal anti-
bodies. It has been found that the prevalence and intensity of OPN
staining signiﬁcantly correlated with the presence of lymph node
metastases and tumor size. It has also been shown that treatment
of human PTC cells with recombinant exogenous OPN stimulated
Matrigel invasion and activated the ERK and AKT/PKB signaling
pathways (Guarino et al., 2005).
Because OPN and CD44v6 overexpression is a common fea-
ture not only of PTC cells that harbor RET/PTC but also of those
expressing BRAF(V600E), the activation of the OPN-CD44v6 axis
appears as one of the end points of the RET-RAS-BRAF-MAPK
oncogenic cascade. This model is consistent with the idea that
OPN expression is also induced by other oncogenes such as RAS
and is dependent on the MAPK pathway and that CD44 splicing
Frontiers in Endocrinology | Cancer Endocrinology May 2012 | Volume 3 | Article 67 | 14
Menicali et al. Thyroid cell transformation by RET/PTC
is under control of the RAS-MAPK pathway as well (Geissinger
et al., 2002; Matter et al., 2002).
The association between lymphocytic inﬁltrates and thyroid
cancer, particularly PTC, in humans is also well documented
(Dailey et al., 1955; Matsubayashi et al., 1995).
The observation that lymphocytic inﬁltration of the thyroid
coexists with cancer suggests that antigens expressed by tumor
cells are responsible for inducing an acquired anti-tumor immune
response (Segal et al., 1985). The study of immune responses
to tumors has primarily focused on the identiﬁcation of tumor-
associated antigens capable of serving as antigenic targets of anti-
tumor immune responses (Van den Eynde et al., 1991; Rosenberg,
1997).Despite the presence of a unique tumor antigen anddemon-
stration of an anti-tumor T cell response, cancer often persists in
mouse tumor models as well as in cancer patients (Lee et al., 1999;
Yu et al., 2005). These observations led to a new vision of inﬂam-
matory cells as a means of tumor support and a necessity for
cancer progression. Inﬂammatory cells provide cytokines, growth
factors, proangiogenetic mediators, and activating anti-apoptotic
pathways that supply a supportive environment for cancer cell
survival and tumor development (Balkwill et al., 2005; de Visser
et al., 2006). These cytokines and growth factors also promote
recruitment and establishment of non-transformed host-derived
ﬁbroblast and endothelial cells, creating a supportive framework
for cancer cells (Moore et al., 1999; Olumi et al., 1999). Moreover,
chronically activated inﬂammatory cells within tumors can play a
protective role in suppressing adaptive anti-tumor responses (Zou,
2005).
The study of the properties of RET/PTC3 has revealed dual
immunological features. First, its constitutive activation can
induce the nuclear transactivation of the NF-κB protein com-
plex (Visconti et al., 1997; Hayashi et al., 2000; Ludwig et al.,
2001), driving the expression of several pro-inﬂammatory medi-
ators (Ghosh and Karin, 2002; Puxeddu et al., 2005a). Second,
RET/PTC3 encodes a chimeric protein that includes peptides that
may be targets of anti-tumor immune responses (Viglietto et al.,
1995; Fusco et al., 2002).
Pufnock and Rothstein hypothesized that combined immune
and neoplastic properties of RET/PTC3 play a role in tumor pro-
gression and that these properties are dependent on the immune
system. They studied the immunological functions of RET/PTC3
in an in vivo cancermodel bymeasuring the recruitment of inﬂam-
matory cells in the tumor microenvironment and the effects on
tumor growth. They found that tumor take in immunocompe-
tent mice was more frequent using RET/PTC3 tumor tissue rather
than the control RET/PTCY588F one (mutation of tyrosine 588
eliminates the transforming ability of RET/PTC3). RET/PTC3
expression correlated with increased CD8+ T cell recruitment at
an early stage of tumor progression and induced recruitment of
myeloid-derived CD11b+ Gr1+ cells into tumors. Thus, tumors
expressing the functional form of RET/PTC3 showed enhanced
inﬁltration of CD8+ lymphocytes, myeloid-derived CD11b+
Gr1+ cells and enhanced growth in immunocompetent mice. In
contrast, RET/PTC3 signaling mutant-expressing tumors main-
tained enhanced inﬁltration of CD8+ lymphocytes but showed
a lower recruitment of CD11b+ Gr1+ cells and a decreased
tumor incidence. Pufnock and Rothstein (2009) proposed that
enhanced transactivation of NF-κB by RET/PTC3 increases the
quantity of secreted cytokines, thereby increasing the number of
myeloid-derived CD11b+ Gr1+ cells recruited into tumor tissue.
Other studies showed that CD11b+ Gr1+ cells had strong sup-
pressive activity on CD8+ tumor-speciﬁc responses (Seraﬁni et al.,
2004).An increase inCD11b+ Gr1+ cells inRET/PTC3-expressing
tumors at an early stage of tumor progression may account for
both the enhanced tumor incidence and larger tumor size observed
despite the high number of CD8+ cells in the tumors.
Recently, it was demonstrated that IFN-γ, derived from
intratumoral-activated T cells, was necessary to activate the sup-
pressive function of CD11b+ Gr1+ cells (Gallina et al., 2006).
These data conﬁrm the notion that the increase of T cell acti-
vation at the tumor site, when combined with localization of
myeloid-derived CD11b+ Gr1+ cells, may promote an environ-
ment supporting cancer progression rather than regression, in
the contest of a potential anti-tumor response. Although Pufnock
and Rothstein suggested that immature CD11b+ Gr1+ cells act
in a suppressive manner on CD8+ cells, further evaluations are
necessary to determine whether this interaction provides direct
help to growing tumors through the secretion of growth factors
rather than, or in addition to, suppression of directed anti-tumor
CD8+ cytolytic responses. At any rate, these data suggest that
RET/PTC3 enzymatic functionsmight independently regulate cel-
lular transformation and anti-tumor lymphocytic responses pro-
moting tumor progression from an early stage. The immunologi-
cal functions seem to inﬂuence both innate and adaptive immune
cells present at the site of the growing tumor. Furthermore,
RET/PTC3-induced NF-κB activation may be the key pathway
governing the immunomodulatory functions of the oncoprotein.
CD8+ T cell inﬁltration of the tumors has been hypothesized
to represent an oncoprotein-reactive lymphocytic accumulation.
The immunogenic capacity of RET/PTC3 fusion protein has been
explored. It was demonstrated that the fusion oncoprotein behaves
like an antigenic non-self protein and a thyroid-speciﬁc tumor
antigen. Although RET/PTC3 is the fusion of two self proteins
to which immunological tolerance is most likely induced, it was
found that the fusion modiﬁes the immunological properties of
the molecules. Interestingly, it was detected that the immuno-
genic response to RET/PTC3 was not directed against the pep-
tide comprising the unique fusion region but rather against the
carboxyl-terminal portion of RET/PTC3 that derives from the
self protein c-RET. Furthermore, transplantation of RET/PTC3-
expressing thyroid cancers into naïve mice resulted in leukocytic
inﬁltration, tumor rejection and induction of RET/PTC3-speciﬁc
T cells (Powell et al., 2003). Thus, the somatic fusion of two unre-
lated self proteins appears able to trigger a uniquely immunogenic
response directed against self epitopes within RET/PTC3.
In summary, RET/PTC appears to activate innate and acquired
immunity in several ways. In a ﬁrst phase, these processes might
be instrumental to tumor elimination or to instauration of equi-
librium between the tumor and the immune system. However,
with time the cancer cell develops progressive immune resis-
tance and gains the ability to tilt the immune response from
restraining to advantageous for the tumor growth. The itera-
tion of evasion mechanisms, associated with the suppression of
different components of the immune system, results ﬁnally in
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immune escape. Moreover, several humoral and cellular compo-
nents of the immune system itself may start to contribute to cancer
maintenance and progression.
DOES RET/PTC IMPACT ON THE PROGNOSTIC
STRATIFICATION OF THYROID CARCINOMA?
Considering the above-described features of RET/PTCs and their
transforming mechanisms, the question of whether RET/PTC has
a role as a thyroid carcinoma tumor marker arises. Regarding thy-
roid cancer diagnostics the answer is yes, and because this issue
goes beyond the aims of this review, we refer to a very recent work
on this topic (Nikiforov, 2011). Regarding prognostic stratiﬁca-
tion, the problem appears to still not be solved. Because of the lack
of extensive reviews on this problem, we dedicate this paragraph
to review the impact of RET/PTC on the prognostic stratiﬁcation
of thyroid carcinoma.
Several studies have tried to associate the presence of a
rearranged RET with clinical parameters. Unfortunately, the
results obtained are controversial. Some studies indicated an asso-
ciation of RET/PTC with a poor prognosis. Conversely, others
indicated an associationwith a goodprognosis. Finally, a last group
could not ﬁnd any association with prognosis at all.
In post-Chernobyl cases, rearrangement-positive PTCs
appeared in a more advanced pT category and more frequently
in the pN1 category at presentation than rearrangement-negative
PTCs (Rabes et al., 2000). Moreover, RET/PTC3, the dominant
rearrangement in the post-Chernobyl PTCs presenting with short
latency,was related to the solid variant of PTC, considered by some
researchers as a more malignant histotype (Thomas et al., 1999;
Rabes et al., 2000). Accordingly, also in sporadic PTCs it was sug-
gested that the rearrangement of the RET proto-oncogene may be
involved in the development of local invasion (pT4) and distant
metastases (Jhiang et al., 1992; Mayr et al., 1997; Bongarzone et al.,
1998).
Other studies indicated the exact opposite. Viglietto and co-
workers showed a higher frequency of RET/PTC rearrangements
in papillary thyroid microcarcinomas compared to clinically sig-
niﬁcant PTCs (42 vs 20%;Viglietto et al., 1995). Soares et al. (1998)
showed the occurrence of the rearrangement in well differentiated
slow growing neoplasms characterized in their view by a “Bonsai”
phenotype. Finally, Tallini et al. (1998) conﬁrmed the association
of RET/PTC rearrangements with well differentiated or under-
centimetric PTCs and showed that in their hands the subset of
RET/PTC-positive PTCs do not progress to more aggressive, less
differentiated tumor phenotypes.
Finally, at least three studies did not show any correlation
between RET/PTC activation and age, sex, tumor size, TNM stag-
ing, number of neoplastic foci, and histological subtype (Learoyd
et al., 1998; Elisei et al., 2001; Puxeddu et al., 2003b).
It is likely that these studies have all been impaired by the lack
of a unique and validated technique to detectRET/PTC rearrange-
ments (see“Prevalence of RET/PTC Rearrangements”). Moreover,
most of them are characterized by a far too small size to arrive
to any consistent conclusion. However, probably with the excep-
tion of radiation-induced PTCs in which RET/PTC might deﬁne
a subset of more aggressive neoplasms, some evidence points to a
good prognostic impact of the rearrangements compared to other
genetic alterations. In the ﬁrst instance, it is clear that PTC harbor-
ing BRAF mutations have the worst outcome (Xing, 2010). Sec-
ond, transgenic mice models conﬁrmed the weaker carcinogenetic
potential on the thyroid gland of RET/PTC rearrangements (Jhi-
ang et al., 1996; Santoro et al., 1996; Powell et al., 1998) compared
to other alterations such as BRAF (Knauf et al., 2005) and RAS
(Vitagliano et al., 2006) mutations. Third, as mentioned above,
the low expression levels of the chimeric oncogenes in vivo, driven
by weak promoters of the RET fusion partner genes, hamper their
transforming potentials (Richardson et al., 2009).
CONCLUSION
In this review, we have tried to summarize 25 years of research
on RET/PTC rearrangement started with its discovery in 1987
(Fusco et al., 1987). Many points regarding its properties of dom-
inant oncogene, its epidemiology, the molecular mechanisms of
its formation, and its transforming features have been clariﬁed.
Doubts remain as to the best laboratory method for its detec-
tion, on its real prevalence and on its impact on clinical behavior
of PTC. Moreover,more complete information on activated signal
transduction pathways, induced gene expression modiﬁcation and
inﬂuences on tumor microenvironment still need to be collected.
However, what we have learned up to now is sufﬁcient to target
RET/PTC with potentially speciﬁc small molecules that inhibit
its tyrosine kinase function (TKIs) in RAI-refractory advanced
PTCs or to develop new compounds with these features. In the
near future we expect that a deeper knowledge of the key biolog-
ical events that drive RET/PTC induced carcinogenesis will allow
us to obtain additional negative modulators of this process to be
placed beside RET/PTC speciﬁc TKIs. In addition, standardization
of the detection method and development of multicenter studies
might allow clariﬁcation of its real prevalence and impact on PTC
prognosis.
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